SCHEMBL3969049

SCHEMBL3969049

COC(=O)c1ccc(C)c(C)c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
PDK2 Q15119 1/20 0.42
PDK4 Q16654 1/20 0.42
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 2/20 0.40
LMNA P02545 1/20 0.40
METAP2 P50579 1/20 0.40
KDM4E B2RXH2 4/20 0.40
GAA P10253 3/20 0.40
GLA P06280 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MAPT P10636 2/20 0.40
ATM Q13315 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773572 0.89 ALDH1A1 (0.46) CA12CA1CA2CA7CA9
Dimethyl Phthalate SCHEMBL29367248 0.89 LMNA (0.46) CA1CA2CA9ALDH1A1MEN1
Dimethyl Phthalate SCHEMBL8874072 0.89 LMNA (0.46) CA1CA2CA9ALDH1A1MEN1
SCHEMBL27464602 0.87 CA12 (0.43) CA12CA1CA2CA7CA9
Ammonia Solution, Strong SCHEMBL9396736 0.87 ALDH1A1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL28067904 0.85 CA12 (0.42) CA12CA1CA2CA7CA9
SCHEMBL9858718 0.84 METAP2 (0.36) CA12CA1CA2CA7CA9
SCHEMBL28080692 0.84 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL30055825 0.82 ALDH1A1 (0.49) CA12CA1CA2CA7CA9
SCHEMBL5772028 0.82 TSHR (0.52) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112692725-B Composition for polishing pad and polishing pad SKC索密思株式会社 2023-05-16 CN disclosed
US-20090318523-A1 BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED 2009-12-24 US disclosed
EP-2081896-A1 BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS Glaxo Group Limited (GB) 2009-07-29 EP disclosed
WO-2008061955-A1 BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318523-A1 BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS PTGER4, PTGER3, HTR4 CA12 4516/4885CA1 4599/4885CA2 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.